BAYRY Stock Recent News

BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.

MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson joined Proactive to chat about the company's transition to commercialization from its R&D focus. He noted the commercialization of its biofertility product TerraSante, which has gained momentum in key US states.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). “Simply put, our ambition is to help more patients with prostate cancer,” said Christine Roth, Executive Vice President, G.

Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PITTSBURGH--(BUSINESS WIRE)--Bayer, UPMC Magee-Womens Hospital and Pennsylvania State Senator Kim Ward (R-Westmoreland County) are collaborating to address the health access gaps that disproportionally impact women in rural communities, specifically those associated with breast health care. The collaboration will provide information on health and food insecurities and will bring mammography breast cancer screenings to those in rural and underserved communities. Arriving on the cusp of Breast Ca.

BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.

Bayer's Q2 2024 results were mixed, with strong Pharmaceuticals performance offsetting challenges in Crop Science and stable Consumer Health results. The reaffirmation of full-year guidance and a significant legal win in the "Schaffner vs. Monsanto" case offer some reassurance to investors. Under all the litigation noise, Bayer is still a strong, innovative business, with potential in both agriculture and pharma.

BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.

Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.

In a big victory for Bayer-owned Monsanto, a federal court overturned a verdict finding the company responsible over claims its Roundup weed killer causes cancer.